OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Nagalla on the Challenges of Managing Thrombocytopenia in MPNs

March 16th 2020

Srikanth Nagalla, MD, discusses the challenges of managing thrombocytopenia in patients with myeloproliferative neoplasms.

Dr. Saint Fleur-Lominy on Differences Between Ruxolitinib and Fedratinib in MPNs

March 16th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the differences between ruxolitinib and fedratinib in the treatment of patients with myeloproliferative neoplasms.

Dr. Ledermann on the Additive Effects of Olaparib and Bevacizumab in Ovarian Cancer

March 14th 2020

Jonathan A. Ledermann, BSc, MD, FRCP, discusses the additive effects of olaparib (Lynparza) and bevacizumab (Avastin) in advanced ovarian cancer.

Dr. Penson on Research With PARP Inhibitors in Ovarian Cancer

March 14th 2020

Richard T. Penson, MD, MRCP, discusses unexpected findings from the phase III SOLO3 trial and ongoing research with PARP inhibitors in ovarian cancer.

Dr. D'Cunha on Surgical Options for High-Risk Patients With Lung Cancer

March 14th 2020

Jonathan D'Cunha, MD, PhD, FACS, discusses surgical options for high-risk patients with lung cancer.

Dr. Cherington on the Use of Immunotherapy and Targeted Therapy in Lung Cancer

March 14th 2020

Chad Cherington, MD, discusses the use of immunotherapy and targeted therapy in lung cancer.

Dr. Katz on Eligibility Criteria for Up-front Surgery in Pancreatic Cancer

March 14th 2020

Matthew H.G. Katz, MD, FACS, discusses the eligibility criteria for up-front surgery in patients with pancreatic cancer.

Dr. Mesa on Challenges With JAK Inhibitors in Myelofibrosis

March 14th 2020

Ruben Mesa, MD, discusses the challenges with using JAK inhibitors in myelofibrosis.

Dr. Putcha on the Utility of Blood-Based Assays in CRC

March 14th 2020

Girish Putcha, MD, PhD, discusses the utility of blood-based assays in colorectal cancer.

Dr. Hershman on Misconceptions With the TAILORx Trial in HR+/HER2- Breast Cancer

March 13th 2020

Dawn L. Hershman, MD, MS, discusses the design of the phase III TAILORx trial in hormone receptor (HR)–positive, HER2-negative breast cancer.

Dr. Desai on Evolving Treatment Approaches in Lymphomas

March 13th 2020

Sameer Desai, MD, discusses current and emerging treatment options under evaluation in lymphomas.

Dr. Pant on Exciting Data With PARP Inhibitors in Pancreatic Cancer

March 13th 2020

Shubham Pant, MD, discusses exciting data with PARP inhibitors in pancreatic cancer.

Dr. Secord on Frontline Maintenance Therapy in Ovarian Cancer

March 13th 2020

Angeles Alvarez Secord, MD, discusses key takeaways from clinical trials that have evaluated frontline maintenance strategies in patients with advanced ovarian cancer.

Dr. Antonarakis on Updated Analysis of the KEYNOTE-199 Trial in mCRPC

March 13th 2020

Emmanuel S. Antonarakis, MBBCh, discusses updated data from the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Dr. Armaghany on Gene Sequencing in CRC

March 13th 2020

Tannaz Armaghany, MD, discusses up-front gene sequencing in patients with colorectal cancer.

Dr. Westin on Potential for Chemo-Free Treatment in Large Cell Lymphoma

March 13th 2020

Jason Westin, MD, MS, FACP, discusses the potential for a chemotherapy-free future in large cell lymphoma.

Dr. Raez on the Benefits of Liquid Biopsies in Newly Diagnosed Lung Cancer

March 13th 2020

Luis E. Raez, MD, discusses the role of liquid biopsies in newly diagnosed patients with lung cancer.

Dr. Sapisochin on Determining Transplant Eligibility in HCC

March 13th 2020

Gonzalo Sapisochin, MD, discusses factors that help determine transplant eligibility in hepatocellular carcinoma.

Dr. Hellmann on Using Trametinib in Low-Grade Ovarian Serous Carcinoma

March 13th 2020

Mira Hellmann, MD, discusses using trametinib to treat patients with low-grade ovarian serous carcinomas.

Dr. Sio on Optimal Radiation Therapy Dose in Locally Advanced NSCLC

March 13th 2020

Terence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.